神经系统疾病诊断市场 - 全球产业规模、份额、趋势、机会和预测（按产品、疾病适应症、最终用户、地区和竞争细分，2019-2029 年）

2023 年，全球神经系统疾病诊断市场估值为94.5 亿美元，预计在预测期内将出现令人印象深刻的成长，到2029 年复合年增长率为7.45%。诊断工具、技术和旨在检测和管理影响大脑、脊髓和周围神经的神经系统疾病的服务。由于多种因素，该市场一直在稳步扩大，包括全球人口老化、神经系统疾病患病率上升、诊断技术的进步以及对早期诊断和干预的认识和重视的提高。在持续的技术进步、人口结构变化和全球医疗保健投资增加的推动下，预计该市场将持续成长。对个人化医疗、人工智慧驱动的诊断和远距医疗解决方案的关注将塑造行业的未来，为市场扩张和改善患者护理结果提供机会。

市场概况
预测期	2025-2029
2023 年市场规模	94.5亿美元
2029 年市场规模	145.8亿美元
2024-2029 年复合年增长率	7.45%
成长最快的细分市场	遗传性神经系统疾病
最大的市场	北美洲

主要市场驱动因素

神经系统疾病的盛行率不断增加

越来越重视早期诊断和疾病管理

诊断技术的进步

主要市场挑战

神经系统疾病的复杂性与异质性

高开发成本和监管障碍

获得专业医疗服务的机会有限

主要市场趋势

生物标记开发和分子诊断的进展

人工智慧 (AI) 和机器学习 (ML) 的集成

远距医疗和远端监控解决方案

细分市场洞察

疾病适应症见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球神经疾病诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（影像、体外诊断）
  • 依疾病适应症（遗传性神经系统疾病、免疫性神经系统疾病、副肿瘤症候群、副蛋白血症神经病变）
  • 按最终使用者（医院和专科诊所、诊断中心、门诊护理中心）
  • 按地区
  • 按公司划分 (2023)
• 市场地图

第 6 章：北美神经疾病诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 按疾病适应症
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲神经疾病诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 按疾病适应症
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区神经疾病诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 按疾病适应症
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲神经疾病诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 按疾病适应症
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲神经疾病诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 按疾病适应症
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 13 章：全球神经疾病诊断市场：SWOT 分析

第14章：竞争格局

• Siemens Healthineers AG
• Koninklijke Philips NV
• Esaote SPA
• NeuroLogica Corp.
• Masimo Corp
• Neusoft Corporation
• CANON MEDICAL SYSTEMS CORPORATION
• Abbott Laboratories Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

Global Neurological Disorder Diagnostics Market was valued at USD 9.45 billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.45% through 2029. The Global Neurological Disorder Diagnostics Market encompasses a wide range of diagnostic tools, technologies, and services aimed at detecting and managing neurological conditions affecting the brain, spinal cord, and peripheral nerves. This market has been expanding steadily due to several factors, including an aging global population, rising prevalence of neurological disorders, advancements in diagnostic technologies, and increased awareness and emphasis on early diagnosis and intervention. Continued growth in this market is expected, driven by ongoing technological advancements, demographic shifts, and increased healthcare investments worldwide. The focus on personalized medicine, AI-driven diagnostics, and telemedicine solutions is set to shape the future of the industry, offering opportunities for market expansion and improved patient care outcomes.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 9.45 Billion
Market Size 2029	USD 14.58 Billion
CAGR 2024-2029	7.45%
Fastest Growing Segment	Genetic Neurological Disorders
Largest Market	North America

Key Market Drivers

Increasing Prevalence of Neurological Disorders

As neurological disorders such as Alzheimer's disease, Parkinson's disease, stroke, and epilepsy become more prevalent globally, there is a heightened demand for early detection and accurate diagnosis. Early diagnosis allows healthcare providers to initiate timely interventions, optimize treatment strategies, and potentially improve patient outcomes. This demand fuels the adoption of advanced diagnostic technologies and drives market growth. The rising prevalence of neurological disorders places a substantial burden on healthcare systems worldwide. Governments and healthcare providers are increasingly investing in improving diagnostic capabilities to address the growing healthcare demands associated with these conditions. This investment drives innovation in diagnostic tools, techniques, and treatments, thereby expanding the market for neurological disorder diagnostics.

Neurological disorders are often age-related, and with global demographic shifts towards an aging population, the incidence of conditions like Alzheimer's disease and Parkinson's disease is expected to rise. Older adults are more susceptible to neurological conditions, necessitating enhanced diagnostic capabilities to manage these diseases effectively. The aging population demographic trend directly correlates with increased demand for neurology diagnostics. The prevalence of neurological disorders encourages continuous advancements in diagnostic technologies such as neuroimaging (MRI, CT, PET scans), genetic testing, and biomarker identification. These technological innovations enable more accurate and comprehensive diagnosis, aiding in early detection and personalized treatment planning. As healthcare providers strive to meet the diagnostic needs of a growing patient population, they increasingly invest in and adopt these advanced diagnostic tools. Neurological disorders not only affect individual patients but also have broader economic and social implications. The economic burden associated with untreated or misdiagnosed neurological conditions motivates healthcare systems to prioritize early detection and effective management through robust diagnostic capabilities. Moreover, societal awareness and advocacy for improved neurological healthcare drive policy reforms and funding initiatives, further supporting market growth in neurology diagnostics.

The increasing prevalence of neurological disorders drives the growth of the Global Neurological Disorder Diagnostics Market by stimulating demand for early detection, prompting healthcare investments in diagnostic technologies, leveraging demographic trends, fostering technological advancements, and addressing economic and social impacts. These factors collectively underscore the market's expansion and innovation in meeting the diagnostic challenges posed by neurological disorders globally.

Growing Emphasis on Early Diagnosis and Disease Management

Early diagnosis of neurological disorders enables healthcare providers to initiate timely and appropriate treatment strategies. Early intervention can slow disease progression, alleviate symptoms, and potentially improve patient outcomes, including quality of life. This clinical benefit encourages healthcare systems and providers to invest in advanced diagnostic technologies capable of detecting neurological conditions at their earliest stages.

There is an increasing recognition of the importance of personalized medicine in neurology, where treatment approaches are tailored to individual patient profiles based on early diagnostic insights. Advanced diagnostic tools, such as genetic testing, biomarker analysis, and neuroimaging techniques (MRI, CT, PET scans), provide detailed information about disease mechanisms and patient-specific characteristics. This shift towards personalized medicine drives the demand for precise and predictive diagnostics, thereby expanding the market for neurology diagnostics. Early diagnosis and proactive disease management in neurology can lead to significant cost savings for healthcare systems. By detecting neurological disorders early, healthcare providers can implement less invasive and more cost-effective treatments, avoid hospitalizations for preventable complications, and reduce long-term healthcare expenditures. This economic incentive motivates healthcare stakeholders to invest in advanced diagnostic technologies that facilitate early detection and management of neurological conditions.

Regulatory agencies and healthcare policymakers increasingly emphasize the importance of early diagnosis and disease management in improving patient outcomes and healthcare efficiency. Supportive regulatory frameworks facilitate the development, approval, and adoption of innovative neurology diagnostics. Clear regulatory pathways for new diagnostic technologies encourage investment in R&D and commercialization, fostering market growth and innovation in neurology diagnostics. Patient empowerment and engagement are driving the adoption of patient-centric care models in neurology. Patients and caregivers are increasingly proactive in seeking early diagnosis and participating in disease management decisions. This trend amplifies the demand for accessible, accurate, and patient-friendly diagnostic tools that facilitate informed decision-making and enhance patient care experiences. Advances in diagnostic technologies, including AI-driven algorithms, digital health solutions, and telemedicine platforms, support early diagnosis and remote monitoring of neurological disorders. These technologies enable healthcare providers to reach underserved populations, facilitate timely consultations, and improve diagnostic accuracy through data-driven insights. The integration of innovative technologies into neurology diagnostics expands market opportunities and enhances healthcare delivery efficiency globally.

The growing emphasis on early diagnosis and disease management drives the growth of the Global Neurological Disorder Diagnostics Market by promoting improved patient outcomes, supporting personalized medicine approaches, reducing healthcare costs, fostering a supportive regulatory environment, empowering patients, and leveraging technological advancements. These factors collectively contribute to market expansion and innovation in neurology diagnostics, meeting the evolving healthcare needs of patients and healthcare providers worldwide.

Technological Advancements in Diagnostics

Advanced neuroimaging techniques, such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), and functional MRI (fMRI), have revolutionized the ability to visualize and characterize neurological conditions. These technologies provide detailed anatomical, functional, and metabolic information about the brain and nervous system, enabling clinicians to make more accurate diagnoses and treatment decisions. The integration of advanced imaging modalities with AI-driven algorithms further enhances diagnostic accuracy by automating image analysis, detecting subtle abnormalities, and predicting disease progression.

Biomarkers, including genetic markers, proteins, and metabolic markers, play a crucial role in diagnosing and monitoring neurological disorders. Technological advancements in biomarker discovery, such as next-generation sequencing (NGS), proteomics, and metabolomics, enable the identification of specific biomarkers associated with neurological conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These biomarkers facilitate early detection, personalized treatment strategies, and monitoring of treatment efficacy, driving the demand for specialized diagnostic tests and enhancing market growth. AI and ML algorithms are transforming neurology diagnostics by analyzing complex datasets, predicting disease outcomes, and optimizing treatment protocols. In neuroimaging, AI algorithms can detect subtle changes in brain structure or function that may indicate neurological disorders, improving diagnostic accuracy and efficiency. AI-powered decision support systems assist clinicians in interpreting diagnostic results, reducing diagnostic errors, and enhancing patient care outcomes. The integration of AI and ML technologies into diagnostic workflows accelerates data-driven insights and innovation in neurology diagnostics, driving market expansion. The adoption of telemedicine platforms and digital health solutions has facilitated remote access to neurological diagnostics and specialist consultations. Telemedicine enables patients in remote or underserved areas to receive timely diagnostic evaluations, reducing geographical barriers to healthcare access. Digital health tools, including mobile applications, wearable sensors, and remote monitoring devices, provide continuous real-time data on patients' neurological status, supporting early detection of symptoms and disease progression monitoring. These technological innovations enhance patient engagement, improve healthcare delivery efficiency, and expand market opportunities for neurology diagnostics globally. Miniaturization of diagnostic devices and the development of point-of-care testing (POCT) technologies enable rapid and on-site diagnosis of neurological disorders. Portable imaging devices, handheld diagnostic tools, and biosensors facilitate immediate diagnostic assessments in clinical settings, emergency departments, and remote locations. These advancements reduce turnaround times for diagnostic results, enhance healthcare provider decision-making capabilities, and improve patient outcomes by enabling timely interventions.

Technological advancements in diagnostics drive the growth of the Global Neurological Disorder Diagnostics Market by enhancing diagnostic accuracy, enabling biomarker discovery, integrating AI and ML capabilities, facilitating telemedicine and digital health solutions, and advancing miniaturization and POCT technologies. These innovations support early diagnosis, personalized treatment approaches, and improved patient care outcomes, positioning neurology diagnostics at the forefront of healthcare innovation globally.

Key Market Challenges

Complexity and Heterogeneity of Neurological Disorders

Neurological disorders encompass a wide spectrum of conditions with diverse etiologies, symptoms, and progression patterns. This complexity poses significant challenges in accurate diagnosis and treatment planning. Many neurological disorders lack specific biomarkers or diagnostic tests, leading to delays in diagnosis, misdiagnosis, and variability in patient outcomes. Healthcare providers face difficulties in standardizing diagnostic protocols and interpreting diagnostic results across different patient populations. Addressing these challenges requires robust research efforts, collaboration among multidisciplinary teams, and advancements in personalized medicine approaches tailored to individual patient profiles.

High Development Costs and Regulatory Hurdles

Developing and commercializing diagnostic technologies for neurological disorders involve substantial research and development (R&D) costs, stringent regulatory requirements, and lengthy approval processes. Innovators must navigate complex regulatory landscapes across different regions, adhering to safety, efficacy, and quality standards set by regulatory authorities like the FDA (Food and Drug Administration) in the United States and the EMA (European Medicines Agency) in Europe. These regulatory hurdles increase time-to-market and financial burdens, particularly for novel diagnostic tests and technologies requiring clinical validation. As a result, some innovative solutions may face delays in market entry or limited accessibility, hindering market growth and innovation adoption.

Limited Access to Specialized Healthcare Services

Disparities in healthcare access and resources contribute to challenges in delivering specialized neurological diagnostics, particularly in rural or underserved regions globally. Access to neurologists, specialized diagnostic facilities (e.g., neuroimaging centers), and advanced diagnostic technologies varies widely, affecting timely diagnosis and management of neurological disorders. Furthermore, socioeconomic factors, insurance coverage limitations, and healthcare infrastructure gaps impact patient access to diagnostic tests and follow-up care. Addressing these access barriers requires healthcare system investments in telemedicine, training of healthcare professionals, and public health initiatives to improve awareness, early detection, and equitable distribution of neurology diagnostics.

Key Market Trends

Advancements in Biomarker Development and Molecular Diagnostics

As technology improves, there's a growing emphasis on biomarkers-indicators of biological processes or conditions within the body. In neurological disorders, biomarkers play a crucial role in early detection, disease monitoring, and treatment response assessment. Advances in molecular diagnostics, such as next-generation sequencing (NGS) and liquid biopsy techniques, enable more precise identification of biomarkers associated with neurological conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These developments enhance diagnostic accuracy, facilitate personalized medicine approaches, and drive market growth by providing clinicians with actionable insights for patient care.

Integration of Artificial Intelligence (AI) and Machine Learning (ML)

AI and ML are revolutionizing healthcare by enhancing diagnostic capabilities, particularly in interpreting complex data from neuroimaging, genetic testing, and clinical assessments. AI algorithms can analyze large datasets to identify patterns, predict disease progression, and optimize treatment strategies. In neurology diagnostics, AI-powered tools aid in image interpretation (e.g., MRI, CT scans), genetic variant analysis, and patient risk assessment. This integration improves diagnostic efficiency, reduces diagnostic errors, and supports clinicians in making informed decisions, thereby fostering market expansion as healthcare providers adopt these technologies to enhance patient outcomes.

Telemedicine and Remote Monitoring Solutions

The adoption of telemedicine and remote monitoring solutions has accelerated, driven by advancements in digital health technologies and the need for accessible neurological care, especially in remote or underserved areas. Telemedicine enables neurologists to remotely diagnose and monitor patients, conduct virtual consultations, and facilitate continuous disease management. Remote monitoring devices, such as wearable sensors and mobile health apps, provide real-time data on patients' neurological status, allowing for early detection of changes and timely intervention. These solutions improve patient access to specialized care, enhance clinical workflow efficiency, and contribute to market growth as healthcare systems embrace telehealth as a sustainable model for neurology diagnostics and management.

Segmental Insights

Disease Indication Insights

Based on the category of Disease Indication, the Genetic Neurological Disorders segment emerged as the dominant in the global market for Neurological Disorder Diagnostics in 2023. Genetic neurological disorders, such as Huntington's disease, Duchenne muscular dystrophy, and certain types of epilepsy, have a notable prevalence worldwide. The incidence rates of these disorders contribute to a consistent demand for diagnostic tools and services. There have been significant advancements in genetic testing technologies, such as next-generation sequencing (NGS) and molecular diagnostics, which have enabled more accurate and comprehensive diagnosis of genetic neurological disorders. These technologies allow for early detection, personalized treatment strategies, and better disease management.

Increased awareness among healthcare professionals and the general population about genetic neurological disorders has led to proactive screening and diagnostic initiatives. Screening programs aim to identify at-risk individuals, facilitating early intervention and genetic counseling. The development of targeted therapies and treatments for specific genetic neurological disorders has further emphasized the need for accurate and early diagnosis. Diagnostic tests are crucial for identifying eligible patients for these therapies and monitoring treatment efficacy. Pharmaceutical companies, diagnostic laboratories, and research institutions are investing heavily in the development of new diagnostic technologies and treatments for genetic neurological disorders. This investment stimulates market growth and innovation in diagnostic approaches. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant in the global Neurological Disorder Diagnostics market in 2023, holding the largest market share in terms of value. North America, particularly the United States and Canada, possesses highly developed healthcare infrastructure. This includes advanced hospitals, diagnostic laboratories, and research facilities equipped with state-of-the-art diagnostic technologies. The availability of such infrastructure supports accurate and timely diagnosis of neurological disorders. The region is at the forefront of technological innovation in healthcare, including neurology diagnostics. Advanced imaging techniques such as MRI (Magnetic Resonance Imaging), CT (Computed Tomography), PET (Positron Emission Tomography), and EEG (Electroencephalography) are widely available and utilized for diagnosing various neurological conditions. North America has a high prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. The aging population, coupled with lifestyle factors, contributes to the increasing incidence of these disorders, driving the demand for diagnostic tests and services.

Government initiatives, policies, and funding support research and development in neurology diagnostics. Regulatory bodies such as the FDA (Food and Drug Administration) in the United States ensure stringent standards for the approval and commercialization of diagnostic technologies, fostering innovation and market growth. North America is home to many leading healthcare providers, academic institutions, and research organizations specializing in neurology and neuroimaging. These institutions collaborate with industry partners to develop and commercialize advanced diagnostic technologies.

Key Market Players

Siemens Healthineers AG

Koninklijke Philips N.V.

Esaote SPA

NeuroLogica Corp.

Masimo Corp

Neusoft Corporation

CANON MEDICAL SYSTEMS CORPORATION

Abbott Laboratories Inc

Report Scope:

In this report, the Global Neurological Disorder Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neurological Disorder Diagnostics Market, By Product:

Imaging In Vitro Diagnostics

Neurological Disorder Diagnostics Market, By Disease Indication:

Genetic Neurological Disorders Immunological Neurological Disorders Paraneoplastic Syndrome Paraproteinemic Neuropathies

Neurological Disorder Diagnostics Market, By End User:

Hospitals and Specialty Clinics Diagnostic Centres Ambulatory Care Centers

Neurological Disorder Diagnostics Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neurological Disorder Diagnostics Market.

Available Customizations:

Global Neurological Disorder Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neurological Disorder Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Imaging, In Vitro Diagnostics)
  • 5.2.2. By Disease Indication (Genetic Neurological Disorders, Immunological Neurological Disorders, Paraneoplastic Syndrome, Paraproteinemic Neuropathies)
  • 5.2.3. By End User (Hospitals and Specialty Clinics, Diagnostic Centres, Ambulatory Care Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map

6. North America Neurological Disorder Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Disease Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neurological Disorder Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Neurological Disorder Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Neurological Disorder Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By End User

7. Europe Neurological Disorder Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Disease Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neurological Disorder Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Neurological Disorder Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Neurological Disorder Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. France Neurological Disorder Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Neurological Disorder Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By End User

8. Asia-Pacific Neurological Disorder Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Disease Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Neurological Disorder Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Neurological Disorder Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Neurological Disorder Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Neurological Disorder Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Neurological Disorder Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By End User

9. South America Neurological Disorder Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Disease Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neurological Disorder Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Neurological Disorder Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Neurological Disorder Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By End User

10. Middle East and Africa Neurological Disorder Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Disease Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neurological Disorder Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Neurological Disorder Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Neurological Disorder Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Neurological Disorder Diagnostics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Siemens Healthineers AG
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Financials (If Listed)
  • 14.1.4. Recent Developments
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Koninklijke Philips N.V.
• 14.3. Esaote SPA
• 14.4. NeuroLogica Corp.
• 14.5. Masimo Corp
• 14.6. Neusoft Corporation
• 14.7. CANON MEDICAL SYSTEMS CORPORATION
• 14.8. Abbott Laboratories Inc.

15. Strategic Recommendations

16. About Us & Disclaimer